CLIN CANCER RES 润色咨询

CLINICAL CANCER RESEARCH

出版年份:1995 年文章数:9146 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:3.7% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2024-03-16 ms9000001180012589 来自上海

    Stage Start Date
    Under Editorial Consideration 2024/3/12
    Under Review 2024/3/11
    Under Editorial Consideration 2024/3/11
    Initial QC 2024/3/7
    Manuscript Submission 2024/3/5

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    21小时前 tou16689595638 来自广西

    还不错,可以冲

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2024-03-08 Dr Young 来自北京

    最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2024-03-03 1157943379 来自广东省

    偏重的研究方向:肿瘤;代谢
    经验分享:Stage Start Date
    Under Editorial Consideration 2024-02-26 07:11:31
    Under Review 2024-02-23 12:33:32
    Under Editorial Consideration 2024-02-23 12:12:07
    Initial QC 2024-02-23 10:33:41
    Manuscript Submission 2024-02-22 12:50:31

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2023-10-03 liuluofei 来自广东省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:非小细胞肺癌
    经验分享:Stage Start Date
    Under Editorial Consideration 2023-10-02 09:57:28
    Under Review 2023-09-21 06:40:54
    Under Editorial Consideration 2023-09-20 08:48:21
    Initial QC 2023-09-18 13:01:13
    Manuscript Submission 2023-09-18 10:44:07

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2024-02-06 ms7000000158522052 来自北京

    Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2023-10-19 ms8000001750053996 来自广东省

    Stage Start Date
    Under Editorial Consideration 2023-10-18 12:49:26
    Under Review 2023-10-18 05:25:13
    Under Editorial Consideration 2023-10-17 09:02:03
    Initial QC 2023-10-14 12:04:38
    Manuscript Submission 2023-10-08 10:02:56
    为什么我有2个编辑审核呢

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2023-10-16 很纯的牛奶 来自吉林省

    Under Editorial Consideration 2023-10-16 06:12:38
    Under Review 2023-10-13 12:56:59
    Under Editorial Consideration 2023-10-13 11:29:39
    Initial QC 2023-10-13 07:26:53
    Manuscript Submission 2023-10-13 04:17:23

    大概率被拒

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2021-07-15 幸运加满

    偏重的研究方向: 肿瘤
    经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2193905, encodeId=ca9a219390591, content=还不错,可以冲, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 16:24:22 CST 2024, time=21小时前, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇,投稿10月28,正式发表2月13,非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向:肿瘤;代谢<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:非小细胞肺癌<br>经验分享:Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2186143, encodeId=06a72186143e1, content=Under Editorial Consideration Under Review Under Editorial Consideration Initial QC Manuscript Submission 2024-02-05 08:28:08 2024-01-26 13:58:52 2024-01-26 09:56:58 2024-01-22 12:02:15 2024-01-22 08:33:06, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ae5486420, createdName=ms7000000158522052, createdTime=Tue Feb 06 09:47:54 CST 2024, time=2024-02-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163165, encodeId=58f42163165b0, content=Under Editorial Consideration 2023-10-16 06:12:38<br>Under Review 2023-10-13 12:56:59<br>Under Editorial Consideration 2023-10-13 11:29:39<br>Initial QC 2023-10-13 07:26:53<br>Manuscript Submission 2023-10-13 04:17:23<br><br>大概率被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Oct 16 20:29:02 CST 2023, time=2023-10-16, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=999642, encodeId=6e35999642e8, content=偏重的研究方向: 肿瘤 <br>经验分享:请问大家怎么确定这个杂志是真外审还是假外审啊~感觉投稿都会有under review这个阶段,但是经常是假外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210707/8fb772c5085640ef95993f5938a945b6/ffe9a19964c24876816fe18c8809fb71.jpg, createdBy=ba3a5543354, createdName=幸运加满, createdTime=Thu Jul 15 08:09:47 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155591, encodeId=f9372155591d5, content=偏重的研究方向:深度学习;临床<br>经验分享:大家都来分享下,几天被拒的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Fri Sep 01 11:34:21 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省)]
    2023-09-01 ms3000001344629820 来自陕西省

    偏重的研究方向:深度学习;临床
    经验分享:大家都来分享下,几天被拒的

    0

共242条页码: 1/25页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分